Does acute pyelonephritis skew outcomes in registrational trials of novel antibiotics for complicated urinary tract infections? A systematic review and meta-analysis

Clicks: 24
ID: 326849
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #253 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) are pooled in registrational RCTs of new antibiotics. We assessed whether outcomes differ between subtypes and which component of the composite endpoint drives any difference. METHODS: Across ten registrational RCTs we estimated the AP-versus-cUTI treatment effect on the composite primary endpoint (clinical cure plus microbiologic eradication at test-of-cure) using random-effects risk ratios, with risk-difference, odds-ratio and leave-one-out sensitivity analyses. Between-arm differences in the composite and its components were correlated across trials; operative definitions and stratified-reporting practices were extracted. RESULTS: From 5,971 patients (3,393 AP; 2,578 other cUTI), AP showed higher overall cure at TOC (pooled RR=1.12; 95% CI 1.03-1.23; I2=82%; 95% prediction interval 0.86-1.46). Between-arm differences in the composite correlated strongly with those in microbiologic eradication (r=0.98) but only weakly with those in clinical cure (r=0.30). In the single trial reporting components stratified by infection subtype (ADAPT-PO), the AP-versus-cUTI gap was larger in microbiologic eradication (+15.6 pp) than in clinical response (+3.5 pp); whether this pattern generalizes to the remaining nine trials could not be publicly tested. Risk of bias was overall some concerns in nine of ten trials, mostly for missing outcome data and selection of the reported result. CONCLUSIONS: AP achieved higher cure rates at TOC than other cUTIs. Heterogeneity in operative AP/cUTI definitions and limited stratified reporting of component outcomes reduce interstudy comparability. Future trials should harmonize definitions, prespecify stratification by infection subtype, and disclose clinical and microbiologic outcomes separately.
Reference Key
openalex_W7204472076 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Giovanni Mori, Tommaso Ceccato, Simone Botti, Simone Giuliano, Carlo Tascini, Stefania Stefani, Massimiliano Lanzafame, Truls Johansen, Tommaso Cai
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag516
URL
https://doi.org/10.1093/cid/ciag516
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.